Somatostatin Receptor-Binding Peptides Labeled with Technetium-99m: Chemistry and Initial Biological Studies
摘要:
The synthesis of peptides which possess a high affinity for the somatostatin receptor and contain a chelator for the radionuclide technetium-99m is described. The target compounds were designed such that they would form stable, oxotechnetium(V) chelate complexes in which the site of metal coordination was well defined and remote from the receptor-binding region. Oxorhenium(V) chelate complexes of these peptides were prepared as nonradioactive surrogates for the technetium complexes. Peptide oxorhenium complexes and Tc-99m complexes eluted closely upon HPLC analysis. The receptor-binding affinities of both the free and rhenium-coordinated species were measured in vitro. The binding affinities of the free peptides (K-i's in the 0.25-10 nM range) compared favorably with [DTPA]octreotide (K-i = 1.6 nM), which, as the indium-lll complex, is already approved for somatostatin receptor (SSTR)-expressing tumor imaging in the United States and Europe. Furthermore, the rhenium-coordinated peptides had binding affinities which, in many cases, were higher than those of the corresponding free peptides, with several complexes having a K-i's of 0.1 nM. Some of the more potent SSTR-binding peptides were labeled with technetium-99m and assessed in an in vivo study with tumor-bearing rats. The Tc-99m-labeled peptides prepared in this study should be useful as SSTR-expressing tumor-imaging agents due to their high SSTR-binding affinities, ease of preparation, and, because they are low molecular weight peptides, expected pharmacokinetics characterized by rapid tracer excretion from the body resulting in high-contrast images.
N-tert-Prenylation of the indole ring improves the cytotoxicity of a short antagonist G analogue against small cell lung cancer
作者:Shaun C. Offerman、Manikandan Kadirvel、Osama H. Abusara、Jennifer L. Bryant、Brian A. Telfer、Gavin Brown、Sally Freeman、Anne White、Kaye J. Williams、Harmesh S. Aojula
DOI:10.1039/c6md00691d
日期:——
antagonist G (SPG), a well-known Small Cell Lung Cancer (SCLC) anticancer agent, we designed a new penta-peptide sequence to include a prenyl moiety on one of the tryptophan residues. The N-tert-prenylated tryptophan analogue was assembled into the pentameric peptide using standard solidphasepeptidesynthesis or liquid phasesynthesis by fragment coupling. In vitro screening showed that the N-tert-prenylation
天然异戊烯化吲哚已被提议作为潜在的抗癌剂。为了利用这一发现来开发新的肽疗法,我们报告了首次将异戊二烯化吲哚掺入一级序列的研究。我们开发了一种合成 N α -Fmoc 保护的色氨酸衍生物的路线,其中异戊烯基与N -吲哚核心相连,使用 Pd( II ) 介导的 2-甲基-2-丁烯 C-H 官能化。基于著名的小细胞肺癌 (SCLC) 抗癌剂 P 物质拮抗剂 G (SPG),我们设计了一种新的五肽序列,在其中一个色氨酸残基上包含异戊二烯基部分。使用标准固相肽合成或通过片段偶联的液相合成将N-叔异戊二烯化色氨酸类似物组装成五聚肽。体外筛选表明,位于五肽 C 端附近的色氨酸残基上吲哚环的N-叔异戊二烯化增强了对 H69 (IC 50 = 2.84 ± 0.14 μM) 和 DMS79 (IC 50 = 4.37 ± 0.44 μM) SCLC 细胞系与未修饰的五肽(H69,IC 50 = 30.74 ±
Somatostatin Receptor-Binding Peptides Labeled with Technetium-99m: Chemistry and Initial Biological Studies
作者:Daniel A. Pearson、John Lister-James、William J. McBride、David M. Wilson、Lawrence J. Martel、Edgar R. Civitello、John E. Taylor、Brian R. Moyer、Richard T. Dean
DOI:10.1021/jm950111m
日期:1996.1.1
The synthesis of peptides which possess a high affinity for the somatostatin receptor and contain a chelator for the radionuclide technetium-99m is described. The target compounds were designed such that they would form stable, oxotechnetium(V) chelate complexes in which the site of metal coordination was well defined and remote from the receptor-binding region. Oxorhenium(V) chelate complexes of these peptides were prepared as nonradioactive surrogates for the technetium complexes. Peptide oxorhenium complexes and Tc-99m complexes eluted closely upon HPLC analysis. The receptor-binding affinities of both the free and rhenium-coordinated species were measured in vitro. The binding affinities of the free peptides (K-i's in the 0.25-10 nM range) compared favorably with [DTPA]octreotide (K-i = 1.6 nM), which, as the indium-lll complex, is already approved for somatostatin receptor (SSTR)-expressing tumor imaging in the United States and Europe. Furthermore, the rhenium-coordinated peptides had binding affinities which, in many cases, were higher than those of the corresponding free peptides, with several complexes having a K-i's of 0.1 nM. Some of the more potent SSTR-binding peptides were labeled with technetium-99m and assessed in an in vivo study with tumor-bearing rats. The Tc-99m-labeled peptides prepared in this study should be useful as SSTR-expressing tumor-imaging agents due to their high SSTR-binding affinities, ease of preparation, and, because they are low molecular weight peptides, expected pharmacokinetics characterized by rapid tracer excretion from the body resulting in high-contrast images.